Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania

Table 2 Treatment responses in patients treated with artesunate/amodiaquine, artemether/lumefantrine and dihydroartemisinin/piperaquine in Tanzania: PCR uncorrected

Year	Drug/site	N	PD3	Excluded/lost	LCF	LPF	ACPR	Kaplan–Meier
Year	Drug/site	N	n (%)	n (%)	% (95% CI)	% (95% CI)	% (95% CI)	% (95% CI)
2011	ASAQ
	Ujiji	73	0	8 (11.0)	13.8 (6.5–24.7)	10.8 (4.4–20.9)	75.4 (63.1–85.2)	76.1 (64.0–84.6)
	Kibaha	29	0	4 (13.8)	0 (0.0–13.7)	0 (0.0–13.7)	100 (86.3–100)	100
	AL
	Muheza	32	2 (6.3)	2 (6.3)	0 (0.0–11.6)	3.3 (0.1–17.2)	96.7 (82.8–99.9)	96.9 (79.8–99.6)
2012	AL
	Chamwino	26	0	3 (11.5)	0 (0.0–14.8)	4.3 (0.1–21.9)	95.7 (78.1–99.9)	95.7 (72.9–99.4)
	Kyela	44	0	8 (18.2)	5.6 (0.7–18.7)	16.7 (6.4–32.8)	77.8 (60.8–89.9)	78.9 (62.3–88.9)
	Nagaga	62	0	23 (37.1)	0 (0.0–9.0)	0 (0.0–9.0)	100 (91.0–100)	100
2015	AL
	Kyela	80	0	16 (20.0)	4.7 (1.0–13.1)	1.6 (0.0–8.4)	93.8 (84.8–98.3)	94.1 (85.0–97.8)
	DHA-PQ
	Rufiji	82	0	10 (12.2)	1.4 (0.0–7.5)	0 (0.0–5.0)	98.6 (92.5–100)	98.6 (90.8–99.8)

PD3 positive on day 3, LCF late clinical failure, LPF late parasitological failure, ACPR adequate clinical and parasitological response, ASAQ artesunate + amodiaquine, AL artemether + lumefantrine, DHAPQ dihydroartemisinin + piperaquine